XORTX Therapeutics Files 2024 Financials and MD&A
Ticker: XRTX · Form: 6-K · Filed: Mar 26, 2025 · CIK: 1729214
Sentiment: neutral
Topics: financials, reporting, pharmaceutical
TL;DR
XORTX dropped its 2024 financials and MD&A on 3/26 - check it out.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on March 26, 2025, reporting its consolidated financial statements for the years ended December 31, 2024, 2023, and 2022, along with its Management Discussion and Analysis for the year ended December 31, 2024. The company is based in Vancouver, Canada, and operates in the pharmaceutical preparations sector.
Why It Matters
This filing provides investors with the company's audited financial performance and management's perspective on its business operations and outlook for the fiscal year 2024.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, XORTX faces inherent risks related to drug development, regulatory approvals, and market competition, which are detailed in their financial filings.
Key Numbers
- 2024 — Fiscal Year End (Financial reporting period covered)
- 2023 — Fiscal Year End (Financial reporting period covered)
- 2022 — Fiscal Year End (Financial reporting period covered)
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- March 26, 2025 (date) — Filing Date
- December 31, 2024 (date) — Fiscal Year End
FAQ
What specific financial results are detailed in the Consolidated Financial Statements for the years ended December 31, 2024, 2023, and 2022?
The filing indicates that Exhibit 99.1 contains the Consolidated Financial Statements for the years ended December 31, 2024, 2023, and 2022, but the specific figures are not detailed within the provided text.
What is the primary purpose of the Management Discussion and Analysis (MD&A) filed as Exhibit 99.2?
The MD&A for the year ended December 31, 2024, provides management's perspective on the company's financial condition and results of operations.
What is XORTX Therapeutics Inc.'s Standard Industrial Classification (SIC) code?
XORTX Therapeutics Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Where is XORTX Therapeutics Inc. located?
XORTX Therapeutics Inc. has its business and mailing address at Suite 2400 - 745 Thurlow Street, Vancouver, A1, V6E 0C5.
Who signed the Form 6-K on behalf of XORTX Therapeutics Inc.?
Allen Davidoff, Chief Executive Officer, signed the Form 6-K on behalf of XORTX Therapeutics Inc. on March 25, 2025.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 26, 2025 by Allen Davidoff regarding XORTX Therapeutics Inc. (XRTX).